SUSTAINABILITY REPORT 2013-15

People Overview Self Managed Teams Mechanisation Safety Overview The Parivartan     Journey Progress on     Roadmap Incident Statistics Robust Governance Standardised     Processes Enhanced Awareness Capability Building Safety Infrastructure Safety Audits Quality Overview Top-down    Accountability Quality by Design Quality Culture     Transformation Quality Assurance Quality     Best Practices All Time Audit     Readiness Availability Overview Strategic Sourcing Risk Management Product    Rationalisation Success stories Environment Overview Roadmap Energy Management Emissions Water Waste Case Study KPIs Community Overview Focus Areas Education Livelihoods Healthcare Infrastructure     Initiatives Creating Change     Makers Productivity Overview Productivity Streams Case Study PACE Update Initiatives Engineering Excellence Overview Digitisation Automation Mechanisation Lean Manufacturing Capital Equipment Strategy Predictive Maintenance Continuous Improvement Overview Continuous     Improvement     at Work Best Practices Annexures GRI Index Acronyms Assurance Statement   Summary Report     ECONOMIC PERFORMANCE FINANCIALS Highlights    |    Economic Value Generated    |    Economic Value Distributed    |    Reinforcing Revenues    |    Local Leverage Reinforcing Revenues Our mandate is to create greater access to affordable medicines and reach patients worldwide. Towards this pursuit, we continue to innovate, stay ahead of the curve and develop new and differentiated products. Prolific Pipeline R&D is in the DNA of Dr. Reddy's. In the last four years alone, we have committed over 8.5% of our consolidated revenues to R&D. Testimony to this commitment are our 170 ANDAs, over 500 DMFs and 86 patents filed in the last five years. The reporting period too was a fulfilling period for our product development team. FY14 13 US filings were made in FY14, which include 1 NDA filing under the section 505(b)(2) and 12 ANDA filings, bringing the cumulative ANDA filings till date to 209. 12 DMFs were filed in the US, 13 in Europe and 36 in other countries.   FY15 As on March 31, 2015, the ANDA pipeline has 68 ANDAs pending approval with the USFDA, of which 43 are Para IV applications and we believe 13 to have 'first-to-file' status. 12 DMFs were filed in the US and 16 in Europe. As on March 31, 2015, there were 735 cumulative DMF filings.   Robust Product Portfolio With every new product, we inch closer to our mission of ensuring good health for all. FY14 54 new products of which 9 were launched in the US, 11 in Europe, 23 in emerging markets and 11 in India. FY15 61 new products of which 12 were launched in the US, 11 in Europe, 20 in emerging markets and 18 in India.